Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)

NCT05159778 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Neoplasm of Breast

Interventions

BIOLOGICAL: Imprime PGG
BIOLOGICAL: Pembrolizumab

Sponsor

HiberCell, Inc.

Collaborators

[object Object]